Wire · operational-macro
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
AstraZeneca invested $2 billion in Summit Therapeutics to support late-stage development of ivonescimab, with an FDA decision expected by November 14; uniQure's shares dropped nearly 40% after disappointing four-year data on its Huntington's disease gene therapy; the FDA has recently approved multiple high-profile drugs.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to reassess risk in gene therapy investments after uniQure’s drop shows long-term data can significantly change valuations. With AstraZeneca backing Summit’s late-stage asset, regulatory milestones remain major value drivers this quarter.
◆ Coverage
1 source · 30 Sep 2026
◆ Related on Wire
◆ Topics